Interestingly, lipoprotein lipase has been shown to modulate HCV access [47]. the last two years, HCV therapy has been profoundly improved with the approval of direct acting antivirals LM22A-4 in the clinical practice (examined in [2]). The new gold standard for treatment has a better sustained virological response rate with significant reduction of the treatment period and less side effects. Despite significant improvements in HCV therapy, the drug resistance and genotype specific efficacy are still issues LM22A-4 to be considered. HCV contamination affects lipid metabolism and cholesterol homeostasis in particular. The association of HCV with lipid metabolism has long been noticed in clinical practice. Liver biopsies of infected patients present LM22A-4 an increase of neutral lipids in cytosolic lipid droplets [3]. Non-A and non-B hepatitis has been associated with liver steatosis, frequent hypobetalipoproteinemia and reduced blood levels of cholesterol (examined in [4]). It is worth noting that patients infected by genotype 3 viruses are more prone to severe steatosis, suggesting that specific viral sequences are responsible for lipid accumulation in the liver (examined in [5]). Although several mechanisms have been proposed to account for the viral steatosis, no experimental model clearly recapitulates the phenotype observed in humans. HCV treatment by interferon alpha and ribavirin restores the cholesterol and the lipoproteins levels in individual sera [6]. At the same time, initial computer virus purification from infected patients sera CACNLB3 revealed the low density of the virions and their association with apolipoproteins [7]. HCV is an enveloped positive-stranded RNA computer virus that belongs to theFlaviviridaefamily. The viral genome is usually translated into a polypeptide, which is usually sequentially processed into ten mature proteins (Physique 1). The structural proteins core and the envelope proteins (E1 and E2) lie at the N-terminus of the polyprotein. The non-structural proteins NS3, NS4A, NS4B, NS5A and NS5B are located at the C-terminus. Between the structural and the nonstructural proteins are two proteins most likely non-structural (p7 and NS2), which are dispensable for replication, but essential for assembly [8]. == Physique 1. == Genomic business of HCV and protein synthesis. The HCV genome contains a single open reading frame flanked by 5 and 3 non-coding regions. The 5 NTR contains an internal ribosome access site (IRES). After its synthesis, the HCV polyprotein is usually cleaved by host transmission peptidase (reddish vertical arrows) and by viral encoded proteases (NS2 and NS3/4A) as indicated by corresponding arrows. An additional cleavage removing the carboxy-terminal region of the core protein is usually mediated by cellular transmission peptide peptidase (green vertical arrow). The functions of the individual proteins are indicated in the text. LM22A-4 Core protein associates with the viral RNA to form the nucleocapsid. E1 and E2 envelope glycoproteins form a heterodimer, which is most likely the functional unit of the viral envelope. The p7 polypeptide is usually a small hydrophobic protein, which forms an ion channel, and it is involved in viral assembly and secretion. NS2 is usually a multifunctional protein essential for both assembly and replication by its function as an autocatalytic cysteine protease. The N-terminal domain name of NS3 is the second viral protease that processes the viral polypeptide towards C-terminus, whereas the C-terminal domain name of NS3 has a helicase function. NS4A is usually a small hydrophobic protein that serves as a cofactor for NS3 serine protease. NS4B protein induces the rearrangement of the intracellular membranes assuring the framework for viral replication. NS5A is usually a multifunctional protein involved in replication and assembly. NS5B is the viral RNA-dependent RNA polymerase that forms a replication complex together with NS3, NS4A, NS4B and NS5A [9]. Over twenty-five years of research has revealed the molecular mechanisms of the association between HCV and lipid metabolism. The emergence of an infectious system able to sustain strong amplification of HCV in LM22A-4 cell culture (HCVcc) boosted our understanding of the role of lipids in each step of the viral life cycle [10,11,12]. Lipid metabolism is usually deeply involved in the molecular mechanisms of the HCV infectious cycle. While HCV is usually a lipoviroparticle that uses lipid-related factors for access, viral replication is usually associated with profound changes of intracellular membrane architecture and viral assembly and secretion take place in the microenvironment of the endoplasmic reticulum (ER) and lipid droplets (LD) overlapping with the very-low density lipoprotein (VLDL) secretion pathway. The aim of.